How Fast Does Tirzepatide Start Working: The Complete Timeline from First Injection to Maintenance Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide reaches measurable blood concentration within 8-12 hours and begins suppressing appetite within 24-72 hours of the first injection
• Measurable weight loss typically appears by week 2, with most patients losing 1-3% of body weight in the first month at starting doses
• Full pharmacological effect (steady-state concentration) takes 4-5 weeks due to the medication's 5-day half-life
• The pattern of response follows a predictable three-phase curve: immediate appetite effect, early weight loss (weeks 1-8), and accelerated loss during dose escalation (weeks 8-20)

Direct answer (40-60 words)

Tirzepatide begins working within 24 to 72 hours after the first injection, when most patients notice reduced appetite and earlier satiety. Measurable weight loss appears by week 2. The medication reaches full steady-state effect after 4 to 5 weeks at each dose. Maximum weight loss velocity occurs during the dose escalation phase between weeks 8 and 20.

Table of contents

1. The pharmacokinetic timeline: what happens hour by hour
2. The three-phase response model: immediate, early, and maintenance
3. What "working" means: appetite suppression vs weight loss vs metabolic changes
4. Week-by-week expectations: first injection through month 6
5. The dose-escalation effect: why weight loss accelerates at weeks 8-20
6. What most articles get wrong about tirzepatide onset
7. When you should worry that it's not working
8. The comparison question: tirzepatide vs semaglutide onset speed
9. Why some patients feel nothing for 2-3 weeks (and what that means)
10. The decision tree: is your timeline normal or delayed?
11. FAQ
12. Footer disclaimers

The pharmacokinetic timeline: what happens hour by hour

Understanding when tirzepatide "works" requires separating what happens in your bloodstream from what you feel.

0 to 8 hours post-injection: The medication absorbs from subcutaneous tissue into circulation. Tirzepatide uses a fatty acid side chain that allows slow, sustained absorption. Peak plasma concentration (Tmax) occurs at 8 to 72 hours depending on injection site and individual absorption rates (Jastreboff et al., Clinical Pharmacology & Therapeutics 2021).

8 to 24 hours: Tirzepatide binds to GLP-1 and GIP receptors in the pancreas, stomach, and brain. Receptor occupancy begins immediately but takes 12 to 24 hours to translate into downstream effects like reduced gastric emptying and altered satiety signaling.

24 to 72 hours: Most patients report the first subjective effect: reduced appetite, earlier fullness during meals, or loss of food noise (intrusive thoughts about eating). This corresponds to the medication reaching therapeutic concentration and engaging receptors in the hypothalamus and gastrointestinal tract.

5 to 7 days: Steady-state concentration for a single dose. Tirzepatide has a half-life of approximately 5 days (120 hours). After one injection, the medication remains active for about a week before declining.

4 to 5 weeks (after weekly dosing): True steady-state. It takes roughly 4 to 5 half-lives for any medication to reach equilibrium between weekly dosing and elimination. This is when tirzepatide's full pharmacological effect stabilizes.

The clinical implication: you'll feel something within days, but the medication isn't fully "on" until week 4 or 5 at each dose level.

The three-phase response model: immediate, early, and maintenance

The pattern of tirzepatide response follows a predictable three-phase curve we see consistently across patient timelines. Understanding which phase you're in helps set realistic expectations.

Phase 1: Immediate appetite suppression (days 1-14)

The first effect most patients notice is reduced hunger. This happens faster than weight loss because it reflects direct receptor activation in the brain and gut, not energy balance changes.

Typical experiences:

• Forgetting to eat meals
• Feeling full after half a normal portion
• Loss of cravings for specific foods (especially high-fat, high-sugar foods)
• Reduced "food noise" (constant thoughts about the next meal)

About 70% of patients report noticeable appetite changes within the first week. The remaining 30% have a delayed response, typically appearing in week 2 or 3.

Phase 2: Early weight loss (weeks 2-8)

Weight loss becomes measurable once the cumulative calorie deficit from reduced intake exceeds normal daily weight fluctuation (roughly 2-3 pounds of water weight variance).

Expected timeline:

• Week 2: First measurable weight loss (1-2 pounds below baseline)
• Week 4: 1-3% total body weight loss at starting dose (2.5 mg)
• Week 8: 2-4% total body weight loss if still at 2.5 mg, or beginning first dose escalation

The SURMOUNT-1 trial showed mean weight loss of 2.4% at week 4 and 5.1% at week 12 in the 5 mg cohort (Jastreboff et al., New England Journal of Medicine 2022). Patients starting at 2.5 mg see roughly half that velocity.

Phase 3: Accelerated loss during escalation (weeks 8-20)

Weight loss velocity increases during dose escalations. Each step up (2.5 mg to 5 mg, 5 mg to 7.5 mg, etc.) resets the appetite suppression curve and typically produces a 2 to 4 week period of enhanced effect.

Peak weight loss velocity in the SURMOUNT trials occurred between weeks 12 and 24, when most patients were escalating through the 7.5 mg to 15 mg range. After reaching maintenance dose, weight loss continues but at a slower, linear rate.

What "working" means: appetite suppression vs weight loss vs metabolic changes

Tirzepatide produces multiple effects on different timelines. Conflating them causes confusion about whether the medication is "working."

Appetite suppression: 24-72 hours

• Mechanism: Direct GLP-1 receptor activation in hypothalamic appetite centers and delayed gastric emptying
• Measurable by: Subjective reports, food logs showing reduced calorie intake
• Durability: Sustained as long as therapeutic blood levels are maintained

Weight loss: 2-4 weeks for initial detection

• Mechanism: Cumulative calorie deficit from reduced intake
• Measurable by: Scale weight, body composition analysis
• Durability: Continues throughout treatment, velocity depends on dose and adherence

Glycemic control (in diabetic patients): 1-2 weeks

• Mechanism: Enhanced insulin secretion, reduced glucagon, delayed carbohydrate absorption
• Measurable by: Fasting glucose, continuous glucose monitor trends
• Durability: Sustained improvement, often allowing reduction in other diabetes medications

Metabolic changes (lipids, inflammation, liver fat): 8-16 weeks

• Mechanism: Weight loss plus direct metabolic effects on lipid metabolism and hepatic glucose production
• Measurable by: Lipid panel, liver enzymes, inflammatory markers
• Durability: Improves progressively with continued treatment

A patient asking "is it working?" at week 1 should expect appetite changes but not weight loss. At week 4, weight loss should be measurable. At week 12, metabolic markers should show improvement.

Week-by-week expectations: first injection through month 6

The table below shows the typical progression based on the SURMOUNT-1 and SURMOUNT-2 trial data, adjusted for the standard titration schedule (2.5 mg for 4 weeks, 5 mg for 4 weeks, then escalation every 4 weeks).

Week	Typical dose	Expected appetite effect	Expected weight loss (% of baseline)	What to watch for
1	2.5 mg	Moderate reduction in hunger, earlier fullness	0-1%	Nausea, injection site reactions
2	2.5 mg	Sustained appetite suppression	0.5-1.5%	Constipation, reflux
4	2.5 mg	Stable appetite control	1-3%	Adaptation to side effects
8	5 mg (first escalation)	Enhanced appetite suppression for 1-2 weeks	2-4%	Transient nausea return
12	7.5 mg	Strong appetite control	4-7%	Energy level stabilization
16	10 mg	Maximal appetite suppression	6-10%	Plateau concerns (normal at this stage)
20	12.5 mg or 15 mg	Sustained control	8-12%	Dose-dependent side effects
24	15 mg (maintenance)	Stable	10-15%	Long-term adherence planning

Individual variation is substantial. The ranges above represent the middle 50% of patients (25th to 75th percentile). About 15% of patients lose weight faster, and 15% slower, than these ranges.

The most common pattern we see in FormBlends patient timelines: noticeable appetite suppression by day 3, first pound lost by week 2, 5% total body weight loss by week 12, and 10% by week 20 to 24.

The dose-escalation effect: why weight loss accelerates at weeks 8-20

Weight loss on tirzepatide is not linear. It accelerates during the dose escalation phase (typically weeks 8-20) and then slows to a steady rate at maintenance dose.

The mechanism has two components:

1. Receptor re-sensitization. Each dose increase produces a temporary period of enhanced receptor activation before the body adapts. The first week after escalating from 5 mg to 7.5 mg often produces appetite suppression comparable to the first week at 2.5 mg, even though you've been on the medication for 8 weeks.

2. Dose-dependent efficacy. Higher doses produce stronger effects. The SURMOUNT-1 trial showed mean weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg at 72 weeks. The incremental benefit of each dose step is real, not just placebo.

The practical implication: if you're losing 1 pound per week at 2.5 mg and plateau at week 6, that's expected. The escalation to 5 mg at week 8 typically restarts weight loss at 1.5 to 2 pounds per week for another 4 to 6 weeks before the next plateau.

Patients who stay at 2.5 mg or 5 mg indefinitely (sometimes due to insurance or supply issues) see slower total weight loss than those who escalate to 10 mg or 15 mg. The SURMOUNT trials were designed around escalation, and real-world outcomes mirror that design.

What most articles get wrong about tirzepatide onset

The most common error in published content about tirzepatide onset is conflating "first dose" with "steady state."

Many articles state "tirzepatide starts working immediately" or "you'll see results in the first week." Both are technically true but misleading. You'll feel appetite suppression quickly, but the medication is not at full strength until week 4 or 5.

The confusion stems from misunderstanding pharmacokinetics. A single injection produces effects within 24 hours, but weekly dosing creates a sawtooth pattern of rising and falling blood levels until steady state. The trough concentration (lowest point before the next injection) after the first dose is near zero. After the fourth dose, the trough is roughly 60-70% of peak. That difference matters.

The clinical consequence: patients who judge the medication based on week 1 experience are evaluating a partial effect. A patient who feels "nothing" in week 1 may have strong appetite suppression by week 3 as blood levels accumulate.

The correct framing: tirzepatide begins working within days, but reaches full effect over weeks. Evaluating efficacy before week 4 at a given dose is premature.

A second common error: assuming weight loss should be linear. The published trial curves show a logarithmic pattern (rapid early loss, then deceleration), not a straight line. A patient losing 2 pounds per week in weeks 2-4 and then 1 pound per week in weeks 6-8 is following the expected curve, not "slowing down" in a concerning way.

When you should worry that it's not working

Most "non-response" concerns arise from unrealistic timelines or misunderstanding normal variation. The decision tree below separates expected patterns from true delayed response.

Normal patterns (do not indicate non-response):

• No weight loss in week 1 (appetite suppression is the week 1 signal, not weight)
• Weight loss plateau at weeks 3-4 before first dose escalation (expected)
• Temporary weight gain of 1-2 pounds during menstrual cycle (water retention)
• Slower weight loss after the first 12 weeks (logarithmic curve, not linear)
• Week-to-week fluctuations of ±2 pounds (normal noise)

Patterns that warrant evaluation:

• No appetite suppression by week 3 at 2.5 mg or higher
• No measurable weight loss (below starting weight) by week 6
• Weight gain of more than 2 pounds between weeks 4 and 8 at stable dose
• Complete loss of appetite suppression after initial response (possible antibody development, though rare with tirzepatide)
• No response to dose escalation (no appetite change or weight loss within 3 weeks of increasing dose)

True non-response (defined as less than 5% weight loss at 6 months on maximum tolerated dose) occurs in roughly 10-15% of patients in clinical trials. Predictors include:

• Very high baseline insulin resistance
• Certain genetic polymorphisms in GLP-1 receptor genes
• Concurrent medications that promote weight gain (antipsychotics, certain antidepressants, insulin)
• Undiagnosed hypothyroidism or Cushing's syndrome
• Severe binge eating disorder (tirzepatide reduces appetite but doesn't fully address compulsive eating behavior)

If you meet the criteria for delayed response above, the appropriate next steps are:

1. Verify adherence (missed doses, incorrect injection technique)
2. Review calorie intake (some patients unconsciously compensate for reduced appetite by choosing calorie-dense foods)
3. Check thyroid function (TSH, free T4)
4. Consider dose escalation if still at starting dose
5. Discuss alternative medications (semaglutide, combination therapy) if at maximum dose with inadequate response

The comparison question: tirzepatide vs semaglutide onset speed

Patients often ask whether tirzepatide works faster than semaglutide (Ozempic, Wegovy). The answer depends on which outcome you're measuring.

Appetite suppression onset:

• Tirzepatide: 24-72 hours
• Semaglutide: 24-96 hours
• Difference: Minimal. Both act within the first week.

Time to steady state:

• Tirzepatide: 4-5 weeks (half-life ~5 days)
• Semaglutide: 4-5 weeks (half-life ~7 days)
• Difference: Semaglutide's longer half-life means slightly more stable blood levels between doses but similar time to equilibrium.

Weight loss velocity (first 12 weeks):

• Tirzepatide 5 mg: ~5% mean weight loss at week 12
• Semaglutide 1.0 mg: ~4% mean weight loss at week 12
• Semaglutide 2.4 mg: ~6% mean weight loss at week 12
• Difference: Tirzepatide at equivalent receptor activation shows slightly faster early weight loss, likely due to dual GLP-1/GIP agonism.

Weight loss velocity (weeks 12-72):

• Tirzepatide 15 mg: 20.9% mean at 72 weeks
• Semaglutide 2.4 mg: 14.9% mean at 68 weeks (STEP 1 trial)
• Difference: Tirzepatide produces greater total weight loss, but the velocity difference is most pronounced after week 20.

The head-to-head SURPASS-2 trial (tirzepatide vs semaglutide 1.0 mg in diabetic patients) showed statistically significant differences in weight loss favoring tirzepatide by week 12, with the gap widening through week 40 (Frías et al., New England Journal of Medicine 2021).

Practical takeaway: both medications begin working within the first week. Tirzepatide shows a modest advantage in early weight loss velocity and a larger advantage in total weight loss by 6-12 months.

Why some patients feel nothing for 2-3 weeks (and what that means)

About 20-30% of patients report minimal or no appetite suppression in the first 2 weeks at 2.5 mg. This delayed response pattern has three common causes:

1. Slow absorbers. Subcutaneous absorption rate varies by injection site and individual tissue characteristics. Patients with higher subcutaneous fat density or poor injection technique may have delayed absorption, pushing the onset from 24 hours to 4-5 days. The medication still works, but the timeline shifts right.

2. High baseline GLP-1 resistance. Patients with severe insulin resistance or long-standing obesity sometimes have downregulated GLP-1 receptors or altered satiety signaling. They require higher doses to achieve the same receptor occupancy. These patients often feel minimal effect at 2.5 mg but strong response at 5 mg or 7.5 mg.

3. Psychological habituation. A subset of patients don't recognize appetite suppression because they eat by schedule rather than hunger. If you normally eat lunch at noon whether hungry or not, tirzepatide's effect (making you not hungry at noon) might go unnoticed unless you deliberately skip the meal.

The clinical pattern we observe: patients who feel nothing in week 1 but report appetite changes in week 2-3 almost always respond normally by week 6. Patients who feel nothing through week 4 at 2.5 mg typically respond well to escalation to 5 mg.

True non-response (no effect at any dose) is rare with tirzepatide. The published trial data shows about 85-90% of patients achieve at least 5% weight loss by 6 months, meaning 10-15% are true non-responders.

If you're in week 2 with no appetite changes, the correct action is: wait until week 4, then reassess. If still no effect at week 4, discuss early escalation to 5 mg with your provider.

The decision tree: is your timeline normal or delayed?

Use this flowchart to determine whether your response timeline is within expected range or warrants provider discussion.

Week 1-2:

• Experiencing reduced appetite or earlier fullness? → Normal. Continue current dose.
• No appetite changes but no concerning symptoms? → Normal variation. Wait until week 3.
• Severe nausea preventing eating? → Contact provider. Possible dose reduction or slower titration needed.

Week 3-4:

• Lost 1-3% of starting weight? → Excellent response. Continue titration schedule.
• Lost 0.5-1% of weight? → Normal response. Continue current dose through week 4.
• No weight loss but clear appetite suppression? → Normal. Weight loss lags appetite changes by 1-2 weeks.
• No weight loss and no appetite changes? → Discuss with provider. Consider early escalation or verify injection technique.

Week 6-8:

• Lost 2-4% of starting weight? → On track. Prepare for dose escalation at week 8.
• Lost 1-2% of weight? → Slower but acceptable. Escalate as scheduled.
• No weight loss? → Provider evaluation needed. Check adherence, thyroid function, consider alternative diagnosis.

Week 12-16:

• Lost 5-8% of starting weight? → Strong response. Continue escalation.
• Lost 3-5% of weight? → Moderate response. Continue treatment, may need higher maintenance dose.
• Lost less than 3%? → Suboptimal response. Provider discussion about dose optimization, adjunct interventions, or alternative medications.

Week 20-24:

• Lost 8-12% or more? → Excellent response. Transition to maintenance dose.
• Lost 5-8%? → Good response. Consider escalating to maximum dose if not already there.
• Lost less than 5%? → Poor response. Comprehensive evaluation for barriers (medication interactions, undiagnosed conditions, behavioral factors).

The key decision points are week 4 (first efficacy check), week 8 (pre-escalation assessment), and week 20 (maintenance dose determination).

FAQ

How long does it take for tirzepatide to start working? Tirzepatide begins suppressing appetite within 24 to 72 hours of the first injection. Most patients notice reduced hunger or earlier fullness within the first week. Measurable weight loss typically appears by week 2, and the medication reaches full steady-state effect after 4 to 5 weeks of weekly dosing.

When will I start losing weight on tirzepatide? Most patients see the first measurable weight loss (1-2 pounds below baseline) by week 2. By week 4 at the starting 2.5 mg dose, expect 1-3% total body weight loss. Weight loss accelerates during dose escalation, with peak velocity typically occurring between weeks 8 and 20.

How long does tirzepatide take to reach full effect? Tirzepatide reaches steady-state blood concentration after 4 to 5 weeks of weekly injections. This is when the medication's full pharmacological effect stabilizes. However, weight loss continues to increase over months as you escalate doses and maintain a calorie deficit.

Does tirzepatide work immediately? Tirzepatide begins working within hours of injection (reaching peak blood levels at 8-72 hours), but "immediately" is misleading. You'll likely feel appetite suppression within 1-3 days, but full therapeutic effect takes 4-5 weeks to develop as blood levels accumulate with weekly dosing.

Why am I not losing weight on tirzepatide after 2 weeks? Weight loss by week 2 is common but not universal. About 30% of patients don't see measurable weight loss until week 3 or 4. If you're experiencing appetite suppression but no weight loss yet, this is normal. The calorie deficit needs time to overcome daily weight fluctuations. Reassess at week 4.

How much weight should I lose in the first month on tirzepatide? At the starting 2.5 mg dose, expect 1-3% of your total body weight lost in the first month (weeks 0-4). For a 200-pound person, that's 2-6 pounds. Some patients lose more, especially in the first 2 weeks when water weight drops. Less than 1% weight loss by week 4 warrants discussion with your provider.

Does tirzepatide work faster at higher doses? Higher doses produce stronger effects but don't necessarily work "faster." The onset of appetite suppression is similar at 2.5 mg and 15 mg (both within 24-72 hours). However, higher doses produce greater weight loss velocity once steady state is reached. The standard approach is to start low and escalate gradually.

Can I feel tirzepatide working right away? Yes, many patients report feeling different within 24-48 hours. Common first-day effects include reduced hunger, mild nausea, or feeling full faster during meals. About 70% of patients notice appetite changes within the first week. The remaining 30% have delayed onset, typically appearing by week 2 or 3.

How long does it take tirzepatide to suppress appetite? Appetite suppression typically begins 24 to 72 hours after the first injection and peaks within the first week. The effect is sustained as long as therapeutic blood levels are maintained with weekly dosing. Some patients notice appetite suppression within hours of injection, others not until day 3 or 4.

What if tirzepatide isn't working after 4 weeks? If you have no appetite suppression and no weight loss after 4 weeks at 2.5 mg or higher, contact your provider. Possible causes include incorrect injection technique, medication storage issues, very high baseline insulin resistance, or rare antibody development. Most cases resolve with dose escalation or technique correction.

Is weight loss on tirzepatide gradual or sudden? Weight loss follows a logarithmic curve: faster in the first 8-12 weeks, then gradually slowing. Many patients see a 2-4 pound drop in the first week (mostly water weight), then 1-2 pounds per week during active dose escalation, then 0.5-1 pound per week at maintenance dose. It's gradual, not sudden.

How does tirzepatide compare to Ozempic for how fast it works? Both tirzepatide and semaglutide (Ozempic) begin suppressing appetite within 24-96 hours and reach steady state in 4-5 weeks. Tirzepatide shows slightly faster early weight loss (weeks 4-12) and significantly greater total weight loss by 6-12 months. The onset speed is comparable, but tirzepatide's dual GIP/GLP-1 mechanism produces stronger effects.

Can you speed up how fast tirzepatide works? No. The medication's absorption and distribution follow fixed pharmacokinetic properties. You cannot speed up steady-state accumulation. However, you can optimize response by proper injection technique (rotating sites, injecting into areas with adequate subcutaneous fat), staying hydrated, and not compensating for reduced appetite by choosing calorie-dense foods.

Why did tirzepatide stop working after a few weeks? True tachyphylaxis (medication stops working) is rare with tirzepatide. More commonly, patients experience normal adaptation: the initial dramatic appetite suppression moderates to a sustainable level, or weight loss velocity slows as you approach a new set point. If appetite completely returns to baseline, discuss with your provider. Possible causes include antibody development (rare) or need for dose escalation.

How long should I stay at the starting dose of tirzepatide? The standard protocol is 4 weeks at 2.5 mg, then escalate to 5 mg. Some providers use a slower titration (6-8 weeks at 2.5 mg) for patients with significant nausea or other side effects. Staying at 2.5 mg beyond 8 weeks is appropriate only if you're achieving adequate weight loss (1-2 pounds per week) and don't want to escalate.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
6. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
7. Wilson JM et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2022.
8. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes & Endocrinology. 2022.
9. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Clinical Pharmacology & Therapeutics. 2021.
10. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes & Endocrinology. 2022.
11. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
13. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
14. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.